glp 1 bmi What Do You Need to Qualify for Semaglutide GLP-1? GLP-1 Use Has More Than

TLDR...I made it one month (barely)

Recent developments underscore the relevance of GLP-1R agonists in addressing the complex interplay of cardiovascular-kidney-metabolic (CKM) syndrome, microvascular dysfunction, and metabolic-associated steatohepatitis (MASH)

Epub 2024 Feb 5

Take control of your gut health today.

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

On the flipside, there are challenges: for example, concerns about cost to healthcare systems and equity of access for patients with the greatest unmet needs, or the possible impact on Medtech currently used by patients suffering from obesity related conditions for example knee replacements for overweight patients with eroded joints or CPAP machines for sleep apnoea, a complication of obesity